New Jersey
Civil Justice Institute

  • Helpful Links
  • Contact Us
  • HOME
  • ABOUT US
    • Our Mission
    • Membership
    • Our Staff
  • ISSUES & ADVOCACY
  • OUR WORK IN THE COURTS
  • NEWSROOM
  • GET INVOLVED

Fairness. Justice.
Rule of Law.

Tag Archives: Pharmaceutical Litigation

The One They’ve Been Waiting For

September 29, 2017News, Top StoriesClass Actions, Expert Evidence, Legal Reform, New Jersey Courts, New Jersey Supreme Court, Pharmaceutical LitigationNJCJI

New Jersey is an outlier. Though nearly 40 states and the federal court system have adopted similar rules governing the admissibility of expert evidence, New Jersey has stuck with an older rule. Continue reading →

Top News Clips for July 15-28

July 28, 2017News, Recent NewsClass Actions, Food Law, New Jersey Bar Association, Pharmaceutical Litigation, Statute of LimitationsNJCJI

A selection of the need-to-know civil justice news for July 15-28. Continue reading →

Top News Clips for the Week of June 17-23

June 23, 2017News, Recent NewsArbitration, Class Actions, Outrageous Lawsuits, Pharmaceutical Litigation, SCOTUSNJCJI

A selection of the need-to-know civil justice news for the week of June 17-23. Continue reading →

Top News Clips for the Week of April 29-May 5

May 5, 2017News, Recent NewsFood Law, New Jersey Courts, Pharmaceutical Litigation, Trial LawyersNJCJI

A selection of the need-to-know civil justice news for the week of April 29-May 5. Continue reading →

Top News Clips for the Week of June 24-30

June 29, 2017News, Recent NewsClass Actions, New Jersey Courts, Outrageous Lawsuits, Pharmaceutical Litigation, SCOTUSNJCJI

A selection of the need-to-know civil justice news for the week of June 24-30.

Continue reading →

What Does the Latest SCOTUS Ruling on Mass Actions Mean for New Jersey?

June 23, 2017News, Top StoriesClass Actions, New Jersey Courts, Pharmaceutical Litigation, SCOTUSNJCJI

Earlier this week, the United States Supreme Court issued its ruling in a closely watched case concerning state based mass actions. The decision, which shuts down certain forms of forum shopping, might lead to more lawsuits being filed in New Jersey state courts because of our state’s plaintiff-friendly laws and the fact that many major businesses call New Jersey home. Continue reading →

Decision Invites More Out-Of-State Plaintiffs

January 24, 2017News, Top StoriesNew Jersey Courts, New Jersey Supreme Court, Pharmaceutical Litigation, Statute of LimitationsNJCJI

Court's opinion in McCarrell v. Hoffmann La RocheThe New Jersey Supreme Court has released its opinion in a long-running lawsuit over the acne medicine Accutane. Instead of throwing out the case as time-barred like NJCJI suggested it do, the Court adopted a new test for determining what statute of limitations should apply in case brought by an out-of-state plaintiff.

 

“It’s disappointing the Court decided to go in this direction,” said NJCJI chief counsel Alida Kass. “It is very likely that plaintiffs whose claims are time-barred in other states will now try to bring their lawsuits here. As the opinion’s author noted during oral arguments, plaintiffs are attracted to our courts because they like our evidence rules and our expert witness rules, so I guess we should now add our statute of limitations to that list. It really distorts the policy choices that have been made by the New Jersey legislature.”

 

Click here to read the court’s full opinion in McCarrell v. Hoffmann-La Roche Inc. and Roche Laboratories Inc.

 

 

Top News Clips for the Week of October 15-21

October 21, 2016News, Recent NewsClass Actions, New Jersey Courts, New Jersey Supreme Court, Pharmaceutical Litigation, TCCWNANJCJI

A selection of the need-to-know civil justice news for the week of October 15-21.

 

NJ Time Limits Should Apply To Accutane Case, Justices Told

Jeannie O’Sullivan | Law360

The attorney for an Accutane user seeking to reinstate his $25 million jury verdict over the acne drug’s adverse effects urged the New Jersey Supreme Court on Thursday to apply the state’s statute of limitations rules to the case, emphasizing the Garden State’s role as a “vanguard” of pharmaceutical law.

Read more.

 

Justices Hear Arguments in $25 Million Accutane Verdict Appeal

Michael Booth | New Jersey Law Journal

Lawyers argued before the New Jersey Supreme Court Thursday over whether an appeals court erred in overturning a $25 million verdict against a pharmaceutical company because the plaintiff violated the statute of limitations in the state where he lives.

Read more.

 

TCCWNAFighting Website Suit, Vita-Mix Points To Similar Dismissal

Cara Salvatore | Law360

Counsel for blender maker Vita-Mix told a New Jersey federal judge on Wednesday that the recent dismissal of a similar suit by a judge citing the U.S. Supreme Court’s Spokeo ruling casts a shadow on the class action against the company over its website terms of use.

Read more. 

 

TCCWNAHertz Wins Toss Of Rewards Program Pricing Class Action

Jeannie O’Sullivan | Law360

The Hertz Corporation on Thursday ducked a class action alleging it failed to specify if a pricing provision in its Gold Plus rewards program applies in New Jersey, with a federal judge invoking the Supreme Court’s Spokeo standard by ruling the customer leading the suit failed to prove he was injured by the omission.

Read more.

 

Follow @NJCivilJustice on Twitter for even more news.

 

Is New Jersey Still a Hot Spot for Pharmaceutical Litigation?

September 1, 2016News, Top StoriesNew Jersey Courts, Pharmaceutical LitigationNJCJI

New Jersey is a hot spot for litigation.New Jersey has a reputation it needs to rid itself of. No, we’re not talking about the hit our state took from being stereotyped as the home of Snooki and the rest of the Jersey Shore gang. What we’re talking about is our reputation as a magnet for pharmaceutical lawsuits. Although we have seen some positive changes in our court system over the past few years, our status as the nation’s medicine chest is still threatened by excessive litigation.

Continue reading →

Top News Clips for the Week of February 27-March 4

March 4, 2016News, Recent NewsClass Actions, New Jersey Supreme Court, Outrageous Lawsuits, Pharmaceutical LitigationNJCJI

A selection of the need-to-know civil justice news for the week of February 27-March 4. Continue reading →

Posts navigation

← Older posts

Newsletter Sign Up




© 2022 NJCJI. All rights reserved.

Follow us on:

  • twitter
  • linkedin

TWITTER FEED TWITTER FEED

  • https://t.co/DlWbCRFBea, Jul 1
  • https://t.co/xl0stnCZfj NJCJI President Anthony Anastasio testified this week about the implications of NJ Senate… https://t.co/o55d5pA29b, Jun 24
  • https://t.co/x2z9vrW707 Thank you to @PPAGInc, @GenovaBurns, and @PBWTLaw for your support of the 2022 Spring Event!, Jun 21
  • Institute for Legal Reform Releases Update on Third-Party Litigation Funding https://t.co/UQDqeUQ712, Apr 15
  • The American Tort Reform Association issued a report about the National Association of Attorneys General. https://t.co/14sYVCKPrY, Apr 8

    QUICK CONTACT



    Please enter the code as shown below

    captcha

    New Jersey Civil Justice Institute | 112 West State Street, Trenton, NJ 08608 | office: (609) 218-6331 | info@civiljusticenj.org